THE ARISING · Longevity & Healthspan
An Experimental Tau Drug Shows a Signal, but the Trial Missed Its Main Goal
Biogen reported a difference in an early Alzheimer's study extension. By then, the study was no longer a blinded comparison against placebo.
An Alzheimer's drug called diranersen takes a different approach from treatments that clear amyloid: it is designed to reduce the production of tau, another protein implicated in the disease. At the Clinical Trials on Alzheimer's Disease conference, Biogen reported new follow-up from its phase 2 CELIA study. The results are a reason to run a confirmatory trial, not evidence that patients should expect a benefit.
The trial enrolled 416 people with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia. For the first 76 weeks, participants and study staff did not know who received one of three drug regimens or placebo. The prespecified primary test asked whether the clinical response varied with dose at week 76. Biogen previously reported that the trial did not meet that endpoint. Some secondary measures favored the lowest-dose group, but that does not change the result of the primary test.
By week 96 the study had moved into an open-label extension. Biogen reported a 1.09-point difference on the Clinical Dementia Rating–Sum of Boxes, a clinician-rated measure of cognition and everyday function. The analysis compared people who continued their assigned lower dose with people who originally received placebo and entered the extension. By that point, the latter group had received no active doses or one active dose. Participants who continued into the extension are a selected group, and the comparison was no longer blinded. It cannot carry the same weight as a result from a blinded placebo-controlled trial.
During the controlled period, frequently reported adverse events included procedure-related pain, symptoms following lumbar puncture and episodes of confusion. The sponsor reported no new safety signals in the extension; that does not establish long-term safety.
The next test is whether a larger, blinded trial can reproduce a benefit on a prespecified measure people and caregivers care about, with an acceptable burden of harms. Diranersen remains experimental.
CELIA trial registry and primary outcome